Global Ophthalmic Disease Therapeutics Market (2024 Edition): Analysis By Indication (Age-related macular degeneration, Diabetic macular edema, Other retinal disorders), By Therapies, By Distribution Channel, By Region, By Country: Market Insights and For

Global Ophthalmic Disease Therapeutics Market (2024 Edition): Analysis By Indication (Age-related macular degeneration, Diabetic macular edema, Other retinal disorders), By Therapies, By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030)

Executive Summary

Azoth Analytics has released a research report titled “Global Ophthalmic Disease Therapeutics Market (2024 Edition)” which provides a Age-related macular degeneration analysis of the Global Ophthalmic Disease Therapeutics industry in terms of market segmentation By Indication (Age-related macular degeneration, Diabetic macular edema), By Therapies (Anti VEGF, Antibody - anti-IGF-1R, Eye drops, Other Therapies) By Distribution Channel (Hospital Pharmacies, Retail & Online Pharmacies) for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030.

The report analyses the Ophthalmic Disease Therapeutics Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India). The Global Ophthalmic Disease Therapeutics market showcased growth at a CAGR of 3.81% during 2020-2023. The market was valued at USD 21.92 Billion in 2023 which is expected to reach USD 31.67 Billion in 2030.

Eye diseases are becoming more prevalent, particularly in aging populations. According to the World Health Organization (WHO), over 2.2 billion people globally are affected by vision impairment or blindness, with at least 1 billion cases being preventable or treatable.

The global ophthalmic disease therapeutics market is projected to exhibit robust growth during the forecast period. Factors such as the introduction of innovative treatment options, rising disposable incomes, and expanding healthcare infrastructure are anticipated to propel market expansion.

The rising incidence of lifestyle-related eye diseases, such as diabetic retinopathy and computer vision syndrome, is contributing to market expansion. Advancements in ophthalmic research and development have led to the development of novel therapies, thereby creating new growth opportunities. Additionally, increasing healthcare expenditure and rising disposable incomes are enabling greater access to ophthalmic care, further stimulating market growth.

Moreover, public health initiatives and increased awareness about eye diseases are improving early diagnosis and treatment, particularly in developed regions.

Scope of the Report:

• The report analyses the Ophthalmic Disease Therapeutics Market by Value (USD Billion).
• The report analyses the Ophthalmic Disease Therapeutics Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India).
• The report presents the analysis of Ophthalmic Disease Therapeutics Market for the historical period of 2020-2023, the estimated year 2024 and the forecast period of 2025-2030.
• The report analyses the Ophthalmic Disease Therapeutics Market By Indication (Age-related macular degeneration, Diabetic macular edema, Other retinal disorders)
• The report analyses the Ophthalmic Disease Therapeutics Market By Therapies (Anti VEGF, Antibody - anti-IGF-1R, and Eye drops, and Other Therapies).
• The report analyses the Ophthalmic Disease Therapeutics Market By Distribution Channel (Hospital Pharmacies, Retail & Online Pharmacies).
• The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Indication, By Therapies and By Distribution Channel.
• Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analyzed in the report include Horizon Therapeutics, Viridian Therapeutics, Viatris, Sanofi Novartis, Bayer AG, Teva Pharmaceuticals, F. Hoffmann-La Roche AG, AbbVie, and GSK plc.